{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:07:17Z","timestamp":1790208437749,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clinthera.2017.12.017","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T01:11:42Z","timestamp":1517620302000},"page":"322-332.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects"],"prefix":"10.1016","volume":"40","author":[{"given":"Xiaojie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beining","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoguo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuran","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail Fedorovich","family":"Gordeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.12.017_bib1","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/AAC.01526-13","article-title":"In vivo antibacterial activity of MRX-I, a new oxazolidinone","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.clinthera.2017.12.017_bib2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1086\/661599","article-title":"Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus","volume":"32","author":"Hayakawa","year":"2011","journal-title":"Infect Cont Hosp Epidemiol"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2017.12.017_bib3","first-page":"iv17","article-title":"Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus","volume":"66","author":"Gould","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2017.12.017_bib4","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1021\/jm401931e","article-title":"New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile","volume":"57","author":"Gordeev","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2017.12.017_bib5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijantimicag.2014.02.008","article-title":"Selection and characterisation of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I","volume":"43","author":"Huang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2017.12.017_bib6","first-page":"210","article-title":"Development and validation of a rapid and robust LC-MS\/MS method for quantification of a new oxazolidinone antibiotic MRX-I in human plasma and urine","volume":"14","author":"Zhao","year":"2014","journal-title":"Chin J Infect Chemother"},{"key":"10.1016\/j.clinthera.2017.12.017_bib7","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","article-title":"Automated covariate model building within NONMEM","volume":"15","author":"Jonsson","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2017.12.017_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput Meth Prog Biomed"},{"key":"10.1016\/j.clinthera.2017.12.017_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2017.12.017_bib10","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic effects of linezolid: summary of clinical experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.clinthera.2017.12.017_bib11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10156-010-0182-1","article-title":"Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy","volume":"17","author":"Takahashi","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.clinthera.2017.12.017_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2017.12.017_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bjid.2015.12.007","article-title":"Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections","volume":"20","author":"Alejandro","year":"2016","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"10.1016\/j.clinthera.2017.12.017_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02181-16","article-title":"Single- and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects","volume":"61","author":"Eckburg","year":"2017","journal-title":"Antimicrobial Agents Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181830002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181830002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T01:10:19Z","timestamp":1538442619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181830002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S014929181830002X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.12.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}